Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

INC Research Becomes First Global CRO to Offer Clinical Research Monitor Credential

Published: Thursday, September 12, 2013
Last Updated: Thursday, September 12, 2013
Bookmark and Share
Externally validated program sets global standard for measuring competence of clinical monitors.

INC Research has announced that it is the first global CRO to implement the Clinical Research Monitor Accreditation program, an internationally recognized standard for competence in clinical research monitoring offered through the International Academy of Clinical Research (IAoCR).

The new Clinical Credentialing program standardizes training of clinical research associates (CRAs) and establishes INC Research as the first accredited training center in the U.S.

"INC Research is committed to providing the best clinical development services to our biopharmaceutical partners, including the most highly trained and competent monitoring staff in the industry," said Alistair Macdonald, Chief Operating Officer.

Macdonald continued, "The Clinical Credential program will validate INC Research monitors' capabilities against globally recognized best practices, including recognition and reporting of adverse events, understanding regulatory processes, preparing for successful site initiations and site visits and more. Customers can therefore be confident the CRAs assigned to their studies are not only well trained and field tested, but also that their skills have been certified against an independent quality standard."

By ensuring its CRAs meet the Clinical Credentialing standard, INC is positioned to reduce risks to patients and lower error rates thereby helping to accelerate new treatments to market.

Exceptional training and global recognition of skills also is expected to help attract and retain top clinical research professionals.

Launched in direct response to the industry's growing demand for accreditation of clinical research professionals, IAoCR's credentialing process focuses on independent verification of an individual's ability to monitor clinical trials effectively in real-life situations.

INC Research will train its CRAs, beginning with entry-level monitors, according to the new IAoCR program, a process spanning two to three months including field tests.

"Competent monitors play an essential role in getting new treatments to market faster while protecting the rights and wellbeing of patients involved in clinical trials," said Jacqueline Johnson North, CEO of IAoCR. "That's why offering programs that regulate and standardize training for CRAs is so important. I commend INC Research for being the first global CRO to embrace this program."

Founded in 2011, IAoCR is fast becoming the globally recognized standard for accreditation of professionals working in the international clinical research industry. IAoCR courses and accreditations are recognized by educational institutes and employers globally and are mapped to international qualification frameworks.

Accreditations cover the depth and breadth of clinical research competencies and provide a far more accurate prediction of performance than simply years of experience.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

INC Research and Debiopharm Group ™ Announce Strategic Partnership
Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm’s pipeline.
Wednesday, July 27, 2011
INC Research Completes Acquisition of Kendle International
Strategic combination creates leading global CRO well-positioned to capitalize on trends in drug development outsourcing.
Friday, July 15, 2011
INC Research to Acquire Kendle International for $15.25 per Share in Cash
INC Research will acquire Kendle in an all-cash transaction with a total equity value of approximately $232 million.
Tuesday, May 24, 2011
Patrick Melvin Joins Oncology Leadership Team at INC Research
Therapeutic and operational clinical trials expert strengthens oncology capabilities.
Thursday, February 17, 2011
INC Research Augments Pediatric Clinical Trial Capabilities
Kathy Bohannon brings valuable multi-discipline therapeutic expertise to pediatric trial design and management.
Friday, February 04, 2011
INC Research Expands Alliance Partnership Executive Team With New VP in Europe
INC Research, Inc. have announced Dr Manfred Weiler as VP of Alliance Development based in Europe. Based in Geneva, Dr. Weiler will lead INC Research's European effort to develop new clinical delivery alliances that are aimed at improving outsourced drug development.
Thursday, November 25, 2010
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!